SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following a strong earnings report that showcased robust user growth and improved margins, fueling community speculation about its shift toward becoming a high-margin cash generator. Investors are actively discussing the stock's recent surge as a potential short squeeze and a long-awaited turnaround, with additional optimism surrounding recent subscription price increases and strategic moves into AI-powered features and video content.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an "Overweight" rating from a major investment bank, highlighting its strong data center deals and power infrastructure expertise. The community is buzzing about the potential for a short squeeze and the company's critical role in the expanding AI infrastructure, with many viewing it as a prime beneficiary of hyperscaler capital expenditures.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is a major talking point as Infleqtion, its quantum technology merger target, recently secured a NASA space mission role and a significant U.S. Department of Energy contract, leading many to believe it's severely undervalued compared to other quantum stocks ahead of its anticipated merger and ticker change to INFQ.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as its recent robust earnings beat and impressive high-value client additions are sparking optimism that this could signal a broader recovery for the beleaguered software sector, with many highlighting DDOG's critical role in AI infrastructure.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as investors debate its post-earnings performance, with bulls highlighting the stock's perceived undervaluation at a low single-digit forward P/E and new management's turnaround strategy, while bears express concern over declining margins, debt, and broader fintech sector headwinds. The community is actively discussing a potential short squeeze against the backdrop of significant institutional buying and recent board appointments.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending as it sweetens its all-cash offer for Warner Bros. Discovery (WBD), increasing financial protections and touting a clearer regulatory path compared to Netflix's (NFLX) bid which faces DOJ scrutiny; the community is also discussing PSKY's recent UFC event viewership amidst calls for improved stock performance.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune is seeing a surge in attention after announcing positive Phase 2a trial results for its atopic dermatitis drug EVO301, sparking a battle between bullish traders anticipating a short squeeze and a skeptical community betting against the rally amid claims of overvaluation.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies trends after an earnings report revealed strong revenue and GMV growth, significant cash burn reduction, and a clear path to profitability without needing a capital raise, yet the stock's initial dip has puzzled many long-term investors who view it as the "Amazon of Africa" for an underserved market.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is surging after releasing robust 52-week maintenance data for its atopic dermatitis drug, Rezpeg, showcasing durable efficacy and a clean safety profile. The community is actively discussing the drug's strong competitive positioning, which is further bolstered by recent Nobel Prize recognition validating Treg-based therapies, fueling significant upside potential and buyout speculation.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Amidst mixed recent earnings that saw a financial miss, Oscar Health is heavily discussed due to its ambitious 2026 guidance and record membership growth, fueling a sharp divide between bullish investors anticipating future profitability and skeptical bears questioning the company's ability to deliver on its long-term outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

🚀 $NVAX is up ~12% over the past month — and this move has a real catalyst behind it.

Novavax licensed its Matrix-M adjuvant to $PFE, securing $30M upfront, up to $500M in milestones, and high mid-single-digit royalties, with Pfizer fully responsible for development and commercialization.

⚡ Why this matters:
• Confirms Matrix-M as a scalable platform, not a single-product story
• Creates a capital-light, royalty-driven revenue stream
• Adds another blue-chip validation alongside existing partners
• Shifts NVAX further away from a pure COVID narrative

This looks less like a dead-cat bounce — and more like platform monetization finally getting priced in.

👉 Price target breakdown here 👇
https://www.zacks.com/stock/research/NVAX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-32768&amp;ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_32768

TopShelfStock

Goksel Topbas

Zacks

Pardon Our Interruption

Zacks Research

Novavax Inc

Pfizer Inc

 is up ~12% over the past month — and this move has a real catalyst behind it.

Novavax licensed its Matrix-M adjuvant to 

, securing $30M upfront, up to $500M in milestones, and high mid-single-digit royalties, with Pfizer fully responsible for development and commercialization.

⚡ Why this matters:
• Confirms Matrix-M as a scalable platform, not a single-product story
• Creates a capital-light, royalty-driven revenue stream
• Adds another blue-chip validation alongside existing partners
• Shifts NVAX further away from a pure COVID narrative

This looks less like a dead-cat bounce — and more like platform monetization finally getting priced in.

👉 Price target breakdown here 👇


This account is recognized as an Official Stocktwits Research Partner — working in close collaboration with Stocktwits to deliver in-depth research and market analysis.